A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FB849 Administered in Subjects with Advanced Solid Tumors Alone and in Combination with Pembrolizumab
NCT #
NCT05761223
Condition(s)
Breast Cancer, Colorectal Cancer, Solid Tumor
Molecular Target(s)
HPK1
Drug Classification(s)
Immunotherapy, Small Molecule
Agents(s)
FB849
Phase(s)
I/II
Mechanism of Action
FB849 is a HPK1 inhibitor
Purpose
- How much of the study drug can be given with an acceptable level of side effects
- The effects of the study drug (good and bad)
- How much of the study drug is absorbed into the blood and how fast it is removed
- How the study drug is acting on your body
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.